A phylotype-based analysis highlights the role of drug-naive HIV-positive individuals in the transmission of antiretroviral resistance in the UK

AIDS

Volumn 29, Issue 15, 2015, Pages 1917-1925

  Mourad, Raphaël ^a   Chevennet, François ^a   Dunn, David T ^b   Fearnhill, Esther ^b   Delpech, Valerie ^c   Asboe, David ^d   Gascuel, Olivier ^a   Hue, Stéphane ^e,f  

^a UNIV MONTPELLIER   (France)

^b UCL   (France)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

^d CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

drug resistance; HIV; phylotype; treatment naive

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; RNA DIRECTED DNA POLYMERASE; POL PROTEIN;

ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; GENE MUTATION; GENE SEQUENCE; GENETIC DISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE B; MAJOR CLINICAL STUDY; MOLECULAR CLOCK; PHYLOGENY; PRIORITY JOURNAL; STRUCTURAL GENE; UNITED KINGDOM; VIRUS TRANSMISSION; BIOLOGY; CLASSIFICATION; COHORT ANALYSIS; DISEASE TRANSMISSION; DNA SEQUENCE; DRUG EFFECTS; FEMALE; GENETICS; GENOTYPE; GREAT BRITAIN; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; MOLECULAR EPIDEMIOLOGY; TRANSMISSION; VIROLOGY;

COHORT STUDIES; COMPUTATIONAL BIOLOGY; DISEASE TRANSMISSION, INFECTIOUS; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; GREAT BRITAIN; HIV INFECTIONS; HIV-1; HUMANS; MALE; MOLECULAR EPIDEMIOLOGY; PHYLOGENY; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; SEQUENCE ANALYSIS, DNA;

EID: 84965066057     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000768     Document Type: Article

References (29)

1. May MT, Gompels M, Delpech V, Porter K, Orkin C, Kegg S, et al. Impact on life expectancy of HIV-1 positive individuals of CD4R cell count and viral load response to antiretroviral therapy. AIDS 2014; 28:1193-1202.
2. Tang JW, Pillay D. Transmission of HIV-1 drug resistance. J Clin Virol 2004; 30:1-10.
3. Resistance UKCGoHD. Dolling D, Sabin C, Delpech V, Smit E, Pozniak A, Asboe D, et al. Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study. BMJ 2012; 345:e5253.
4. Hue S, Gifford RJ, Dunn D, Fernhill E, Pillay D, Resistance UKCGoHD. Demonstration of sustained drug-resistant human immunodeficiency virus type 1 lineages circulating among treatment-naive individuals. J Virol 2009; 83:2645-2654.
5. Wagner BG, Garcia-Lerma JG, Blower S. Factors limiting the transmission of HIV mutations conferring drug resistance: fitness costs and genetic bottlenecks. Sci Rep 2012; 2:320.
6. Audelin AM, Gerstoft J, Obel N, Mathiesen L, Laursen A, Pedersen C, et al. Molecular phylogenetics of transmitted drug resistance in newly diagnosed HIV Type 1 individuals in Denmark: a nation-wide study. AIDS Res Hum Retroviruses 2011; 27:1283-1290.
7. Drescher SM, von Wyl V, Yang WL, Boni J, Yerly S, Shah C, et al. Treatment-naive individuals are the major source of transmitted HIV-1 drug resistance in men who have sex with men in the Swiss HIV Cohort Study. Clin Infect Dis 2014; 58:285-294.
8. Lewis F, Hughes GJ, Rambaut A, Pozniak A, Leigh Brown AJ. Episodic sexual transmission of HIV revealed by molecular phylodynamics. PLoS Med 2008; 5:e50.
9. Chevenet F, Jung M, Peeters M, de Oliveira T, Gascuel O. Searching for virus phylotypes. Bioinformatics 2013; 29:561-570.
10. Yang Z, Rannala B. Molecular phylogenetics: principles and practice. Nat Rev Genet 2012; 13:303-314.
11. UKCHCS Committee. The creation of a large UK-based multi-centre cohort of HIV-infected individuals: the UK Collaborative HIV Cohort (UK CHIC) Study. HIV Med 2004; 5:115-124.
12. Hue S, Brown AE, Ragonnet-Cronin M, Lycett SJ, Dunn DT, Fearnhill E, et al. Phylogenetic analyses reveal HIV-1 infections between men misclassified as heterosexual transmissions. AIDS 2014; 28:1967-1975.
13. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 2009; 4:e4724.
14. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG. The CLUSTAL-X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 1997; 25:4876-4882.
15. Goloboff PA, Farris J, Nixon K. T.N.T.: tree analysis using new technology. http://www.zmuc.dk/public/phylogeny/TNT 2003 [Accessed 17 June 2015].
16. Price MN, Dehal PS, Arkin AP. FastTree 2-approximately maximum-likelihood trees for large alignments. PLoS One 2010; 5:e9490.
17. Fitch WM. Toward defining the course of evolution: minimum change for a specific tree topology. Syst Zool 1971; 20:406-416.
18. Drummond AJ, Rambaut A. BEAST: Bayesian evolutionary analysis by sampling trees. BMC Evol Biol 2007; 7:214.
19. Shapiro B, Rambaut A, Drummond AJ. Choosing appropriate substitution models for the phylogenetic analysis of protein-coding sequences. Mol Biol Evol 2006; 23:7-9.
20. Castro H, Pillay D, Cane P, Asboe D, Cambiano V, Phillips A, et al. Persistence of HIV-1 transmitted drug resistance mutations. J Infect Dis 2013; 208:1459-1463.
21. Schmidt D, Kollan C, Fatkenheuer G, Schulter E, Stellbrink HJ, Noah C, et al. Estimating trends in the proportion of transmitted and acquired HIV drug resistance in a long term observational cohort in Germany. PLoS One 2014; 9:e104474.
22. Charest H, Doualla-Bell F, Cantin R, Murphy DG, Lemieux L, Brenner B, et al. A significant reduction in the frequency of HIV-1 drug resistance in Quebec from 2001 to 2011 is associated with a decrease in the monitored viral load. PLoS One 2014; 9:e109420.
23. Siliciano JD, Siliciano RF. Recent trends in HIV-1 drug resistance. Curr Opin Virol 2013; 3:487-494.
24. de Ronde A, van Dooren M, van Der Hoek L, Bouwhuis D, de Rooij E, van Gemen B, et al. Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus. J Virol 2001; 75:595-602.
25. Cong ME, Heneine W, Garcia-Lerma JG. The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions. J Virol 2007; 81:3037-3041.
26. Martinez-Picado J, Savara AV, Sutton L, D'Aquila RT. Replica-tive fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol 1999; 73:3744-3752.
27. Phillips AN, Cambiano V, Nakagawa F, Brown AE, Lampe F, Rodger A, et al. Increased HIV incidence in men who have sex with men despite high levels of ART-induced viral suppression: analysis of an extensively documented epidemic. PLoS One 2013; 8:e55312.
28. Hall HI, Holtgrave DR, Maulsby C. HIV transmission rates from persons living with HIV who are aware and unaware of their infection. AIDS 2012; 26:893-896.
29. Powers KA, Ghani AC, Miller WC, Hoffman IF, Pettifor AE, Kamanga G, et al. The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study. Lancet 2011; 378:256-268.